Does Successive Intra-articular Injections of Tenoxicam or Meloxicam Affect Treatment of TMJ Displacement

Launched by BENI-SUEF UNIVERSITY · May 3, 2024

Keywords

ClinConnect Summary

This clinical trial is looking at the effects of two medications, Tenoxicam and Meloxicam, when injected directly into the temporomandibular joint (TMJ) of patients who have a specific condition called anterior disc displacement with reduction. This condition affects how the disc in the jaw joint sits, which can cause pain, difficulty opening the mouth, and clicking sounds. The goal of the study is to see if these injections can help relieve symptoms and improve function in the jaw.

To participate in this trial, you need to be between 18 and 45 years old and have been diagnosed with TMJ disc displacement that includes pain and other related symptoms. However, you won't be able to join if you've had previous TMJ surgery, have certain joint problems, or have allergies to the medications used in the injections. If you join the study, you can expect to receive one of the two medications and help researchers understand how effective these treatments are for managing TMJ-related symptoms.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Patients of both sexes with an age range of 18-45 years.
• • 2. Those patients with the radiographic interpretation of unilateral or bilateral (TMJ) anterior disc displacement with reduction with the clinical signs of pain, limitation of mouth opening, and TMJ clicking; Wilkes classification type II.
• Exclusion Criteria:
• • 1. Clinical or radiographic signs of disc displacement without reduction, osteoarthritis, or articular bony changes.
• • 2. Previous (TMJ) surgery, arthrocentesis, or occlusal splints.
• • 3. Any systemic disease affecting the temporomandibular joint's anatomy, mechanical function, or outcome of the proposed treatment.
• • 4. Those Patients with a history of allergic reactions to any components of the injectable solutions.